open access
Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial
Affiliations- Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
- Postgraduate Medical School, University of Hertfordshire, Stevenage, United Kingdom
- Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom
- Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland, Austria
- Center of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland
- Department of Cardiology, Medical University of Vienna, Austria
- Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital, Life Bridge Health System, Baltimore, MD, United States
- National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece
- Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
- Center of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- Department of Cardiology, The Pope John Paul II Hospital, Zamosc, Poland
- Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
- Maria Cecilia Hospital, GVM Care and Research, Cotignola (RA), Ravenna, Italy
- Medizinische Klinik III, Department of Cardiology, Angiology and Pulmology, University Hospital of Heidelberg, Germany
- Department of Cardiology, Voivodeship Hospital, Lomza, Poland
- 1st Department of Cardiology, Medical University of Gdansk, Poland
- Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden
- Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, South Korea
- Department of Cardiology, The Doctor Sokolowski Hospital, Walbrzych, Poland
- University of Eastern Piemont, Maggiore della Carità Hospital, Novara, Italy
- Cardiology Department with the Acute Coronary Syndromes Subdivision, Clinical Provincial Hospital No. 2, Faculty of Medicine, University of Rzeszow, Poland
- Department of Medical-Surgery Sciences and Translational Medicine, University La Sapienza, Rome, Italy
- Pavia, Italy
- 3rd Department of Cardiology, Silesian Center for Heart Diseases, Faculty of Medicine in Zabrze, Medical University of Silesia, Zabrze, Poland
- Department of Cardiology, Medical University of Bialystok, Poland
- Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
- Department of Invasive Cardiology, Center of Postgraduate Medical Education, Central Hospital of the Internal Affairs and Administration Ministry, Warsaw, Poland
- 1st Department and Chair of Cardiology, Medical University of Lodz, Bieganski Hospital, Lodz, Poland
- University of Information Technology and Management in Rzeszow, Poland
- Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College and John Paul II Hospital in Krakow, Poland
- Chair and 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
open access
Abstract
Abstract
Supp./Additional Files (1)
About this articleTitle
Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial
Journal
Issue
Article type
Study Protocol
Pages
148-153
Published online
2021-09-30
Page views
3521
Article views/downloads
728
DOI
10.5603/CJ.a2021.0118
Pubmed
Bibliographic record
Cardiol J 2022;29(1):148-153.
Authors
Jacek Kubica
Piotr Adamski
Diana A. Gorog
Aldona Kubica
Bernd Jilma
Andrzej Budaj
Jolanta M. Siller-Matula
Paul A. Gurbel
Dimitrios Alexopoulos
Jolita Badarienė
Paweł Dąbrowski
Dariusz Dudek
Evangelos Giannitsis
Grzegorz Horszczaruk
Miłosz J. Jaguszewski
Stefan James
Young-Hoon Jeong
Michał Kryjak
Piotr Niezgoda
Małgorzata Ostrowska
Giuseppe Patti
Janusz Romanek
Salvatore Di Somma
Giuseppe Specchia
Udaya Tantry
Mariusz Gąsior
Agnieszka Tycińska
Wojciech Wojakowski
Katarzyna Buszko
Robert Gil
Marcin Gruchała
Jarosław Kasprzak
Andrzej Kleinrok
Jacek Legutko
Maciej Lesiak
Eliano P. Navarese
References (14)- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
- Wallentin L, Becker R, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
- Storey RF, Angiolillo DJ, Bonaca MP, et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol. 2016; 67(10): 1145–1154.
- Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2015; 37(3): 245–252.
- Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791–1800.
- Kubica J, Adamski P, Buszko K, et al. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Eur Heart J Cardiovasc Pharmacother. 2019; 5(3): 139–148.
- Mehran R, Baber U, Sharma S, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019; 381(21): 2032–2042.
- Kubica J, Adamski P, Niezgoda P, et al. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J. 2021; 28(4): 607–614.
- Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction . Eur Heart J. 2019; 40(3): 237–269.
- Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289–1367.
- Zaman A, de Winter RJ, Kogame N, et al. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019; 393(10175): 987–997.
- Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017; 390(10104): 1747–1757.
- Cuisset T, Deharo P, Quilici J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017; 38(41): 3070–3078.
- De Luca L, D'Ascenzo F, Musumeci G, et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention. 2017; 13(4): 459–466.
